Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma
Oncology · 2024
DOI: 10.1159/000538455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2024. Verfasst von Chih-Yang Hsiao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, cyhsiao1102@gmail.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, DNA Methylation, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Lack of biomarkers for follow-up after treatment is a clinical challenge. DNA methylation has been proposed to be a potential biomarker in HCC. However, there is still a lack of evidence of its clinical use. This study aimed to evaluate the value of using plasma Adenomatous Polyposis Coli promoter methylation level (APC-MET) as a potential biomarker in HCC treatment.
Method
A total of 96 patients with HCC at BCLC stage B who underwent local tumor ablation treatment were prospectively included in this study. APC-MET was examined in the plasma of each patient before and 1 month after treatment. The prediction value of APC-MET for survival outcome and disease status after treatment was analyzed and adjusted with alpha-fetoprotein and protein induced by vitamin K absence-II using Cox regression analysis.
Results
Univariate Cox regression analysis showed preoperative APC-MET >0 (HR, 2.9, 95% CI: 1.05–8.05, p = 0.041) and postoperative APC-MET >0 (HR, 3.47, 95% CI: 1.16–10.4, p = 0.026) were both predictors of death, and preoperative APC-MET >0 was a predictor of disease progression after treatment (HR, 2.04, 95% CI: 1.21–3.44, p = 0.007). In multivariate models, preoperative APC-MET >0 was a significant predictor of disease progression after adjusting with the other two traditional biomarkers (HR, 1.82, 95% CI: 1.05–3.17, p = 0.034).
Conclusions
Hypermethylation of APC promoter appears to be a potential biomarker that could predict patient survival and disease progression outcomes in patients with intermediate-stage HCC after local ablation treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan, cyhsiao1102@gmail.com.
- Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan, cyhsiao1102@gmail.com.
- Department of Traumatology, National Taiwan University Hospital, Taipei, Taiwan, cyhsiao1102@gmail.com.
- Phalanx Biotech Group, Hsinchu, Taiwan.
- Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Zitieren
APA
Hsiao, C. Y., Lu, C. Y., Su, H. J., & Huang, K. W. (2024). Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma. Oncology. https://doi.org/10.1159/000538455
Vancouver
Hsiao CY, Lu CY, Su HJ, Huang KW. Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma. Oncology. 2024. doi:10.1159/000538455
BibTeX
@article{Hsiao2024,
author = {Hsiao, Chih-Yang and Lu, Chang-Yi and Su, Hung-Ju and Huang, Kai-Wen},
title = {Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma},
journal = {Oncology},
year = {2024},
doi = {10.1159/000538455}
}
EUVIMED